The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Biosimilars Market Research Report 2024

Global Biosimilars Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1562800

No of Pages : 111

Ask Your Query

Synopsis

A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

The global Biosimilars market was valued at US$ 5727.5 million in 2023 and is anticipated to reach US$ 18790 million by 2030, witnessing a CAGR of 18.0% during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars.

Report Scope

The Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

  • Pfizer
  • Novartis
  • Biocon
  • Biogen
  • Fresenius Kabi AG
  • Boehringer Ingelheim
  • Merck KgaA
  • Mylan
  • Eli Lilly
  • Teva Pharmaceutical
  • Dr. Reddy's Laboratories
  • Amgen
  • Celltrion
  • Samsung Biologics
  • Roche
  • Probiomed
  • Apotex
  • Chong Kun Dang
  • JCR Pharmaceuticals
  • Gan & Lee Pharmaceuticals
  • Gedeon Richter
  • Biocad
  • Coherus Bioscience
  • Stada Arzneimittel AG

Segment by Type

  • Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
  • Recombinant Glycosylated Proteins

Segment by Application

  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  • Others

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Biosimilars Market Overview
1.1 Product Overview and Scope of Biosimilars
1.2 Biosimilars Segment by Type
1.2.1 Global Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
1.2.3 Recombinant Glycosylated Proteins
1.3 Biosimilars Segment by Application
1.3.1 Global Biosimilars Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Blood Disorders
1.3.4 Growth Hormonal Deficiency
1.3.5 Chronic and Autoimmune Disorders
1.3.6 Others
1.4 Global Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Biosimilars Revenue 2019-2030
1.4.2 Global Biosimilars Sales 2019-2030
1.4.3 Global Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilars Market Competition by Manufacturers
2.1 Global Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilars, Product Type & Application
2.7 Biosimilars Market Competitive Situation and Trends
2.7.1 Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilars Players Market Share by Revenue
2.7.3 Global Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilars Retrospective Market Scenario by Region
3.1 Global Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilars Global Biosimilars Sales by Region: 2019-2030
3.2.1 Global Biosimilars Sales by Region: 2019-2024
3.2.2 Global Biosimilars Sales by Region: 2025-2030
3.3 Global Biosimilars Global Biosimilars Revenue by Region: 2019-2030
3.3.1 Global Biosimilars Revenue by Region: 2019-2024
3.3.2 Global Biosimilars Revenue by Region: 2025-2030
3.4 North America Biosimilars Market Facts & Figures by Country
3.4.1 North America Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilars Sales by Country (2019-2030)
3.4.3 North America Biosimilars Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Biosimilars Market Facts & Figures by Country
3.5.1 Europe Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilars Sales by Country (2019-2030)
3.5.3 Europe Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilars Sales by Type (2019-2030)
4.1.1 Global Biosimilars Sales by Type (2019-2024)
4.1.2 Global Biosimilars Sales by Type (2025-2030)
4.1.3 Global Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global Biosimilars Revenue by Type (2019-2030)
4.2.1 Global Biosimilars Revenue by Type (2019-2024)
4.2.2 Global Biosimilars Revenue by Type (2025-2030)
4.2.3 Global Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilars Sales by Application (2019-2030)
5.1.1 Global Biosimilars Sales by Application (2019-2024)
5.1.2 Global Biosimilars Sales by Application (2025-2030)
5.1.3 Global Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global Biosimilars Revenue by Application (2019-2030)
5.2.1 Global Biosimilars Revenue by Application (2019-2024)
5.2.2 Global Biosimilars Revenue by Application (2025-2030)
5.2.3 Global Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Biosimilars Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Biocon
6.3.1 Biocon Corporation Information
6.3.2 Biocon Description and Business Overview
6.3.3 Biocon Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biocon Biosimilars Product Portfolio
6.3.5 Biocon Recent Developments/Updates
6.4 Biogen
6.4.1 Biogen Corporation Information
6.4.2 Biogen Description and Business Overview
6.4.3 Biogen Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Biosimilars Product Portfolio
6.4.5 Biogen Recent Developments/Updates
6.5 Fresenius Kabi AG
6.5.1 Fresenius Kabi AG Corporation Information
6.5.2 Fresenius Kabi AG Description and Business Overview
6.5.3 Fresenius Kabi AG Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Fresenius Kabi AG Biosimilars Product Portfolio
6.5.5 Fresenius Kabi AG Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer Ingelheim Biosimilars Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Merck KgaA
6.6.1 Merck KgaA Corporation Information
6.6.2 Merck KgaA Description and Business Overview
6.6.3 Merck KgaA Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck KgaA Biosimilars Product Portfolio
6.7.5 Merck KgaA Recent Developments/Updates
6.8 Mylan
6.8.1 Mylan Corporation Information
6.8.2 Mylan Description and Business Overview
6.8.3 Mylan Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mylan Biosimilars Product Portfolio
6.8.5 Mylan Recent Developments/Updates
6.9 Eli Lilly
6.9.1 Eli Lilly Corporation Information
6.9.2 Eli Lilly Description and Business Overview
6.9.3 Eli Lilly Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Eli Lilly Biosimilars Product Portfolio
6.9.5 Eli Lilly Recent Developments/Updates
6.10 Teva Pharmaceutical
6.10.1 Teva Pharmaceutical Corporation Information
6.10.2 Teva Pharmaceutical Description and Business Overview
6.10.3 Teva Pharmaceutical Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Teva Pharmaceutical Biosimilars Product Portfolio
6.10.5 Teva Pharmaceutical Recent Developments/Updates
6.11 Dr. Reddy's Laboratories
6.11.1 Dr. Reddy's Laboratories Corporation Information
6.11.2 Dr. Reddy's Laboratories Biosimilars Description and Business Overview
6.11.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Dr. Reddy's Laboratories Biosimilars Product Portfolio
6.11.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Corporation Information
6.12.2 Amgen Biosimilars Description and Business Overview
6.12.3 Amgen Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amgen Biosimilars Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Celltrion
6.13.1 Celltrion Corporation Information
6.13.2 Celltrion Biosimilars Description and Business Overview
6.13.3 Celltrion Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Celltrion Biosimilars Product Portfolio
6.13.5 Celltrion Recent Developments/Updates
6.14 Samsung Biologics
6.14.1 Samsung Biologics Corporation Information
6.14.2 Samsung Biologics Biosimilars Description and Business Overview
6.14.3 Samsung Biologics Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Samsung Biologics Biosimilars Product Portfolio
6.14.5 Samsung Biologics Recent Developments/Updates
6.15 Roche
6.15.1 Roche Corporation Information
6.15.2 Roche Biosimilars Description and Business Overview
6.15.3 Roche Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Roche Biosimilars Product Portfolio
6.15.5 Roche Recent Developments/Updates
6.16 Probiomed
6.16.1 Probiomed Corporation Information
6.16.2 Probiomed Biosimilars Description and Business Overview
6.16.3 Probiomed Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Probiomed Biosimilars Product Portfolio
6.16.5 Probiomed Recent Developments/Updates
6.17 Apotex
6.17.1 Apotex Corporation Information
6.17.2 Apotex Biosimilars Description and Business Overview
6.17.3 Apotex Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Apotex Biosimilars Product Portfolio
6.17.5 Apotex Recent Developments/Updates
6.18 Chong Kun Dang
6.18.1 Chong Kun Dang Corporation Information
6.18.2 Chong Kun Dang Biosimilars Description and Business Overview
6.18.3 Chong Kun Dang Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Chong Kun Dang Biosimilars Product Portfolio
6.18.5 Chong Kun Dang Recent Developments/Updates
6.19 JCR Pharmaceuticals
6.19.1 JCR Pharmaceuticals Corporation Information
6.19.2 JCR Pharmaceuticals Biosimilars Description and Business Overview
6.19.3 JCR Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.19.4 JCR Pharmaceuticals Biosimilars Product Portfolio
6.19.5 JCR Pharmaceuticals Recent Developments/Updates
6.20 Gan & Lee Pharmaceuticals
6.20.1 Gan & Lee Pharmaceuticals Corporation Information
6.20.2 Gan & Lee Pharmaceuticals Biosimilars Description and Business Overview
6.20.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Gan & Lee Pharmaceuticals Biosimilars Product Portfolio
6.20.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.21 Gedeon Richter
6.21.1 Gedeon Richter Corporation Information
6.21.2 Gedeon Richter Biosimilars Description and Business Overview
6.21.3 Gedeon Richter Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Gedeon Richter Biosimilars Product Portfolio
6.21.5 Gedeon Richter Recent Developments/Updates
6.22 Biocad
6.22.1 Biocad Corporation Information
6.22.2 Biocad Biosimilars Description and Business Overview
6.22.3 Biocad Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Biocad Biosimilars Product Portfolio
6.22.5 Biocad Recent Developments/Updates
6.23 Coherus Bioscience
6.23.1 Coherus Bioscience Corporation Information
6.23.2 Coherus Bioscience Biosimilars Description and Business Overview
6.23.3 Coherus Bioscience Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Coherus Bioscience Biosimilars Product Portfolio
6.23.5 Coherus Bioscience Recent Developments/Updates
6.24 Stada Arzneimittel AG
6.24.1 Stada Arzneimittel AG Corporation Information
6.24.2 Stada Arzneimittel AG Biosimilars Description and Business Overview
6.24.3 Stada Arzneimittel AG Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Stada Arzneimittel AG Biosimilars Product Portfolio
6.24.5 Stada Arzneimittel AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilars Industry Chain Analysis
7.2 Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilars Production Mode & Process
7.4 Biosimilars Sales and Marketing
7.4.1 Biosimilars Sales Channels
7.4.2 Biosimilars Distributors
7.5 Biosimilars Customers
8 Biosimilars Market Dynamics
8.1 Biosimilars Industry Trends
8.2 Biosimilars Market Drivers
8.3 Biosimilars Market Challenges
8.4 Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock